Loading…
MindWalk Holdings Corp.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -79.0% over 5Y.
today you would have $221.86▼ -77.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Year-end price | $1.38 | $1.82 | $0.41 | $1.71 | |
| P/S | 3.1x | 4.1x | 7.9x | 1.1x | 2.1x |
| P/B | 2.1x | 5.5x | 3.6x | 0.3x | 0.7x |
| EPS | -$0.31 | -$0.90 | -$1.02 | -$1.07 | |
| Profit margin | -191.29% | -89.66% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NNOXNano-X Imaging Ltd. | $0.83 | — | 0.5x | — | -50.12% | $65.2M |
| RNTXRein Therapeutics, Inc. | $0.76 | — | — | — | -96.42% | $65.74M |
| INMBInmune Bio, Inc. | $2.33 | — | 3.2x | — | -74.82% | $64.67M |
| BOLDBoundless Bio, Inc. | $2.83 |
MindWalk Holdings Corp. operates as a bio-native AI company. The company discovers and develops biologics through HYFT Technology and LensAI platform, as well as develops AI drug discovery and biologics through ReefIQ technology. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.
Company description provided by Yahoo Finance.
| -284.53% |
| -254.06% |
| -128.53% |
| ROE | -95.96% | -118.72% | -127.97% | -73.20% | -45.95% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.0x |
| — |
| -67.86% |
| $64.38M |
| DRIODarioHealth Corp. | $6.77 | — | 0.9x | — | -59.91% | $66.34M |
| EXOZExozymes Inc | $7.17 | — | 18.2x | — | -187.16% | $66.53M |